PT2934521T - Utilização de pidotimod para tratar psoríase - Google Patents

Utilização de pidotimod para tratar psoríase

Info

Publication number
PT2934521T
PT2934521T PT128122215T PT12812221T PT2934521T PT 2934521 T PT2934521 T PT 2934521T PT 128122215 T PT128122215 T PT 128122215T PT 12812221 T PT12812221 T PT 12812221T PT 2934521 T PT2934521 T PT 2934521T
Authority
PT
Portugal
Prior art keywords
pidotimod
treat psoriasis
psoriasis
treat
Prior art date
Application number
PT128122215T
Other languages
English (en)
Inventor
Mailland Federico
Caserini Maurizio
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of PT2934521T publication Critical patent/PT2934521T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT128122215T 2012-12-19 2012-12-19 Utilização de pidotimod para tratar psoríase PT2934521T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/076088 WO2014094840A1 (en) 2012-12-19 2012-12-19 Use of pidotimod to treat psoriasis

Publications (1)

Publication Number Publication Date
PT2934521T true PT2934521T (pt) 2017-03-03

Family

ID=47520054

Family Applications (1)

Application Number Title Priority Date Filing Date
PT128122215T PT2934521T (pt) 2012-12-19 2012-12-19 Utilização de pidotimod para tratar psoríase

Country Status (31)

Country Link
US (1) US20150328191A1 (pt)
EP (1) EP2934521B1 (pt)
JP (1) JP6051315B2 (pt)
KR (1) KR20150095773A (pt)
CN (1) CN104869994B (pt)
AR (1) AR094027A1 (pt)
AU (1) AU2012396942A1 (pt)
BR (1) BR112015011391A2 (pt)
CA (1) CA2887878A1 (pt)
CY (1) CY1118645T1 (pt)
DK (1) DK2934521T3 (pt)
EA (1) EA201591185A1 (pt)
ES (1) ES2617235T3 (pt)
HK (1) HK1210937A1 (pt)
HR (1) HRP20161666T1 (pt)
HU (1) HUE031846T2 (pt)
IL (1) IL239429A0 (pt)
LT (1) LT2934521T (pt)
MA (1) MA38155B1 (pt)
ME (1) ME02560B (pt)
MX (1) MX2015008104A (pt)
PH (1) PH12015501210A1 (pt)
PL (1) PL2934521T3 (pt)
PT (1) PT2934521T (pt)
RS (1) RS55436B1 (pt)
SG (1) SG11201503270UA (pt)
SI (1) SI2934521T1 (pt)
SM (1) SMT201700072B (pt)
TN (1) TN2015000142A1 (pt)
WO (1) WO2014094840A1 (pt)
ZA (1) ZA201502573B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015036009A1 (en) * 2013-09-10 2015-03-19 Polichem S.A. Pidotimod for use in the treatment of inflammation-associated diseases
EA201892190A1 (ru) 2016-03-29 2019-04-30 Янссен Байотек, Инк. Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
CN105943505A (zh) * 2016-05-26 2016-09-21 杭州百诚医药科技股份有限公司 一种匹多莫德药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1231723B (it) * 1989-08-11 1991-12-21 Poli Ind Chimica Spa Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
WO2003018011A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-(substituted)-5-(substitutedsulfonyl or sulfanyl)thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase

Also Published As

Publication number Publication date
RS55436B1 (sr) 2017-04-28
TN2015000142A1 (en) 2016-10-03
MA38155B1 (fr) 2016-09-30
EP2934521B1 (en) 2016-11-30
CA2887878A1 (en) 2014-06-26
BR112015011391A2 (pt) 2017-07-11
ME02560B (me) 2017-02-20
AR094027A1 (es) 2015-07-08
CN104869994A (zh) 2015-08-26
HUE031846T2 (hu) 2017-08-28
CN104869994B (zh) 2016-10-12
EA201591185A1 (ru) 2016-02-29
IL239429A0 (en) 2015-07-30
AU2012396942A2 (en) 2015-07-30
ES2617235T3 (es) 2017-06-15
CY1118645T1 (el) 2017-07-12
MX2015008104A (es) 2015-11-06
LT2934521T (lt) 2016-12-27
SG11201503270UA (en) 2015-07-30
EP2934521A1 (en) 2015-10-28
PL2934521T3 (pl) 2017-06-30
ZA201502573B (en) 2016-11-30
JP2016503043A (ja) 2016-02-01
PH12015501210A1 (en) 2015-08-17
HK1210937A1 (en) 2016-05-13
MA38155A1 (fr) 2016-02-29
KR20150095773A (ko) 2015-08-21
AU2012396942A1 (en) 2015-07-02
SMT201700072B (it) 2017-03-08
US20150328191A1 (en) 2015-11-19
SI2934521T1 (sl) 2017-03-31
DK2934521T3 (en) 2017-02-06
WO2014094840A1 (en) 2014-06-26
JP6051315B2 (ja) 2016-12-27
HRP20161666T1 (hr) 2017-01-27

Similar Documents

Publication Publication Date Title
HRP20181628T1 (hr) Spojevi i postupci za njihovu upotrebu
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
EP2905027A4 (en) USE OF MYCOBACTERIUM BRUMAE FOR THE TREATMENT OF BUBBLE CANCER
EP2709665A4 (en) TREATMENT OF PSORIASIS
ZA202207530B (en) Use of phenoxypropylamine compounds to treat depression
HK1210937A1 (en) Use of pidotimod to treat psoriasis
HK1210938A1 (en) Use of pidotimod to treat atopic dermatitis
GB201212717D0 (en) Treatment of musculoskeletal conditions
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201208505D0 (en) Treatment of skin condition